Biobeat was included as Top 10 M&A targets in Medtech

Biobeat have been included in Fierce Biotech’s list of top M&A targets in Medtech, showing the benefits of Biobeat, and its advantage over other players in the wearable monitoring space, with the huge advantage of continuous blood pressure monitoring.

Read the full report: https://www.fiercebiotech.com/special-report/biobeat-fierce-medtech-s-top-10-m-a-targets-for-2020